PHAXIAM Therapeutics S.A. Stock price Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 EUR | -0.50% | +2.23% | -35.22% |
Mar. 21 | Transcript : PHAXIAM Therapeutics S.A., Q4 2023 Earnings Call, Mar 21, 2024 | |
Mar. 20 | PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2023 | - | Sales 2024 * | - | Capitalization | 18.19M 19.65M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.84M | Net income 2024 * | -18M -19.44M | EV / Sales 2023 | - |
Net Debt 2023 * | 3.3M 3.56M | Net Debt 2024 * | 1.7M 1.84M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.7
x | P/E ratio 2024 * |
-2.14
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 92.13% |
Latest transcript on PHAXIAM Therapeutics S.A.
1 week | +0.68% | ||
Current month | -1.81% | ||
1 month | -1.97% | ||
3 months | -33.78% | ||
6 months | -37.85% | ||
Current year | -35.22% |
Managers | Title | Age | Since |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.98 | -0.50% | 5 425 |
24-03-27 | 2.995 | +3.28% | 10,753 |
24-03-26 | 2.9 | 0.00% | 1,202 |
24-03-25 | 2.9 | -1.69% | 6,257 |
24-03-22 | 2.95 | -0.34% | 4,277 |
Real-time Euronext Paris, March 28, 2024 at 12:20 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.03% | 108B | |
+9.39% | 104B | |
+6.58% | 23.66B | |
-12.36% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.58% | 16.19B | |
+4.02% | 13.72B | |
+32.98% | 12.22B |
- Stock
- Equities
- Stock PHAXIAM Therapeutics S.A.
- Stock PHAXIAM Therapeutics S.A. - Euronext Paris